ABCL logo

ABCL
AbCellera Biologics Inc

8,328
Mkt Cap
$1.11B
Volume
395,064.00
52W High
$6.52
52W Low
$1.89
PE Ratio
-7.44
ABCL Fundamentals
Price
$3.51
Prev Close
$3.65
Open
$3.63
50D MA
$3.64
Beta
1.49
Avg. Volume
4.56M
EPS (Annual)
-$0.4901
P/B
1.13
Rev/Employee
$133,679.71
$604.47
Loading...
Loading...
News
all
press releases
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says
AbCellera Biologics (NASDAQ:ABCL) is positioning itself as a more pipeline-driven biotechnology company after more than a decade of platform investment, according to comments from Senior Director of...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL
DNB Asset Management AS purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·9d ago
News Placeholder
What Sparked AbCellera Biologics To Soar Over 9% After Hours
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.read more...
Benzinga·15d ago
News Placeholder
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +83.56% and +565.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
AbCellera Biologics Q4 Earnings Call Highlights
AbCellera Biologics (NASDAQ:ABCL) used its full-year 2025 business update call to emphasize that it has completed its transition toward becoming a vertically integrated, clinical-stage biotech and is...
MarketBeat·16d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Announces Quarterly Earnings Results
AbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus...
MarketBeat·16d ago
News Placeholder
AbCellera Reports Full Year 2025 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. In 2025...
Business Wire·16d ago
News Placeholder
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages
AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has received a consensus recommendation of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat reports. One...
MarketBeat·22d ago
News Placeholder
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday
AbCellera Biologics (NASDAQ:ABCL) will be releasing its Q4 2025 earnings after the market closes on Tuesday, February 24. (View Earnings Report at...
MarketBeat·23d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen raised shares of AbCellera Biologics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·26d ago
<
1
2
...
>

Latest ABCL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.